S&P 500   3,909.61 (+2.58%)
DOW   31,612.99 (+2.20%)
QQQ   323.71 (+3.05%)
AAPL   127.61 (+5.24%)
MSFT   237.09 (+2.03%)
FB   266.50 (+3.45%)
GOOGL   2,069.37 (+2.35%)
TSLA   714.76 (+5.81%)
AMZN   3,141.89 (+1.58%)
NVDA   550.55 (+0.36%)
BABA   242.01 (+1.79%)
CGC   34.76 (+6.14%)
GE   13.22 (+5.42%)
MU   94.66 (+3.42%)
NIO   49.92 (+9.04%)
AMD   86.43 (+2.27%)
T   28.17 (+1.00%)
F   12.03 (+2.82%)
ACB   11.14 (+5.89%)
DIS   195.54 (+3.44%)
BA   224.48 (+5.88%)
NFLX   550.73 (+2.20%)
BAC   35.99 (+3.69%)
S&P 500   3,909.61 (+2.58%)
DOW   31,612.99 (+2.20%)
QQQ   323.71 (+3.05%)
AAPL   127.61 (+5.24%)
MSFT   237.09 (+2.03%)
FB   266.50 (+3.45%)
GOOGL   2,069.37 (+2.35%)
TSLA   714.76 (+5.81%)
AMZN   3,141.89 (+1.58%)
NVDA   550.55 (+0.36%)
BABA   242.01 (+1.79%)
CGC   34.76 (+6.14%)
GE   13.22 (+5.42%)
MU   94.66 (+3.42%)
NIO   49.92 (+9.04%)
AMD   86.43 (+2.27%)
T   28.17 (+1.00%)
F   12.03 (+2.82%)
ACB   11.14 (+5.89%)
DIS   195.54 (+3.44%)
BA   224.48 (+5.88%)
NFLX   550.73 (+2.20%)
BAC   35.99 (+3.69%)
S&P 500   3,909.61 (+2.58%)
DOW   31,612.99 (+2.20%)
QQQ   323.71 (+3.05%)
AAPL   127.61 (+5.24%)
MSFT   237.09 (+2.03%)
FB   266.50 (+3.45%)
GOOGL   2,069.37 (+2.35%)
TSLA   714.76 (+5.81%)
AMZN   3,141.89 (+1.58%)
NVDA   550.55 (+0.36%)
BABA   242.01 (+1.79%)
CGC   34.76 (+6.14%)
GE   13.22 (+5.42%)
MU   94.66 (+3.42%)
NIO   49.92 (+9.04%)
AMD   86.43 (+2.27%)
T   28.17 (+1.00%)
F   12.03 (+2.82%)
ACB   11.14 (+5.89%)
DIS   195.54 (+3.44%)
BA   224.48 (+5.88%)
NFLX   550.73 (+2.20%)
BAC   35.99 (+3.69%)
S&P 500   3,909.61 (+2.58%)
DOW   31,612.99 (+2.20%)
QQQ   323.71 (+3.05%)
AAPL   127.61 (+5.24%)
MSFT   237.09 (+2.03%)
FB   266.50 (+3.45%)
GOOGL   2,069.37 (+2.35%)
TSLA   714.76 (+5.81%)
AMZN   3,141.89 (+1.58%)
NVDA   550.55 (+0.36%)
BABA   242.01 (+1.79%)
CGC   34.76 (+6.14%)
GE   13.22 (+5.42%)
MU   94.66 (+3.42%)
NIO   49.92 (+9.04%)
AMD   86.43 (+2.27%)
T   28.17 (+1.00%)
F   12.03 (+2.82%)
ACB   11.14 (+5.89%)
DIS   195.54 (+3.44%)
BA   224.48 (+5.88%)
NFLX   550.73 (+2.20%)
BAC   35.99 (+3.69%)
Log in
NASDAQ:GLMD

Galmed Pharmaceuticals Stock Forecast, Price & News

$3.96
-0.01 (-0.25 %)
(As of 03/1/2021 03:00 PM ET)
Add
Compare
Today's Range
$3.96
Now: $3.96
$4.20
50-Day Range
$3.37
MA: $4.09
$5.40
52-Week Range
$2.96
Now: $3.96
$6.29
Volume2,852 shs
Average Volume459,153 shs
Market Capitalization$83.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; and a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol. The company was founded in 2000 and is headquartered in Tel Aviv-Yafo, Israel.
Galmed Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448
Employees17
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.04 million
Book Value$3.30 per share

Profitability

Net Income$-20,460,000.00

Miscellaneous

Market Cap$83.61 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

659th out of 1,965 stocks

Pharmaceutical Preparations Industry

329th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$3.96
-0.01 (-0.25 %)
(As of 03/1/2021 03:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

Is Galmed Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Galmed Pharmaceuticals stock.
View analyst ratings for Galmed Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Galmed Pharmaceuticals?

Wall Street analysts have given Galmed Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Galmed Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 37,800 shares, an increase of 49.4% from the January 14th total of 25,300 shares. Based on an average trading volume of 155,400 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the company's shares are short sold.
View Galmed Pharmaceuticals' Short Interest
.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Galmed Pharmaceuticals
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.32).
View Galmed Pharmaceuticals' earnings history
.

How has Galmed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GLMD shares have decreased by 5.0% and is now trading at $4.00.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GLMD?

8 brokerages have issued 12-month price targets for Galmed Pharmaceuticals' shares. Their forecasts range from $8.00 to $33.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $19.50 in the next year. This suggests a possible upside of 387.5% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:
  • Mr. Allen Baharaff, Co-Founder, CEO, Pres & Director (Age 56, Pay $784.86k)
  • Mr. Yohai Stenzler, CFO & Controller (Age 38, Pay $155.34k)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 36, Pay $165.43k)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 54, Pay $242.52k)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 51, Pay $242.28k)
  • Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 38)

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ibex Investors LLC (7.22%), Baker BROS. Advisors LP (0.88%), Renaissance Technologies LLC (0.55%) and Squarepoint Ops LLC (0.10%).

Which institutional investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, and Squarepoint Ops LLC.

Which institutional investors are buying Galmed Pharmaceuticals stock?

GLMD stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Ibex Investors LLC.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $4.00.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals has a market capitalization of $84.45 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

How many employees does Galmed Pharmaceuticals have?

Galmed Pharmaceuticals employs 17 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is www.galmedpharma.com.

Where are Galmed Pharmaceuticals' headquarters?

Galmed Pharmaceuticals is headquartered at 16 TIOMKIN STREET, TEL AVIV L3, 6578317.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.